Glucagon-like peptide: The time is near

Basic and Clinical Pharmacology and Toxicology

Volumn 95, Issue 6, 2004, Pages 249-251

  Huang, Alvin ^a   Raskin, Philip ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENZYME INHIBITOR; GLUCAGON LIKE PEPTIDE 1; POTASSIUM CHANNEL; VOLTAGE GATED CALCIUM CHANNEL;

CELL DENSITY; CELL DIFFERENTIATION; CELL PROLIFERATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; GENE TRANSFER; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RELEASE; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; SATIETY; STOMACH EMPTYING; WEIGHT REDUCTION;

ANTIGENS, CD26; DIABETES MELLITUS, TYPE 2; GENE THERAPY; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HALF-LIFE; HUMANS; INSULIN; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS;

EID: 10644228556     PISSN: 17427835     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2004.t01-1-pto950501.x     Document Type: Letter

References (22)

1. Behme, M. T., J. Dupre & T. J. McDonald: Glucagon-like peptide 1 improved glycemic control in type 1 diabetes. BMC Endocrine Disorders 2003, 3, 1-9.
2. DeFronzo, R. A.: Pharmacologic therapy for type 2 diabetes mellitus. Ann. Intern. Med. 1999, 131, 281-303.
3. Egan, J. M., G. S. Meneilly, J. F. Habener, et al.: Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state. J. Clin. Endocrinol. Metab. 2002, 87, 3768-3773.
4. Egan, J. M., A. Bulotta, H. Hui, et al.: GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells. Diab. Metab. Res. Rev. 2003, 19, 115-123.
5. Farilla, L., A. Bulotta, B. Hirshberg, et al.: Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003, 144, 5149-5158.
6. Gromada, J., B. Brock, O. Schmitz & P. Rorsman: Glucagon-like peptide: Regulation of insulin secretion and therapeutic potential. Basic & Clinical Pharmacology & Toxicology 2004, 95, 252-262.
7. Gutniak, M., C. Orskov, J. J. Holst, et al.: Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. New Engl. J. Med. 1992, 326, 1316-1322.
8. Hui, H., R. Yu, C. Bousquet, et al.: Transfection of pancreatic-derived β-cells with a minigene encoding for human glucagon-like peptide-1 regulates glucose-dependent insulin synthesis and secretion. Endocrinology 2002, 143, 3529-3539.
9. Kieffer, T. J. & J. F. Habener: The glucagon-like peptides. Endocrin. Rev. 1999, 20, 876-913.
10. Kim, J. G., L. L. Baggio, D. P. Bridon, et al.: Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes 2003, 52, 751-759.
11. Meneilly, G. S., C. H. S. McIntosh, R. A. Pederson, et al.: Effect of glucagon-like peptide 1 (7-36 amide) on insulin-mediated glucose uptake in patients with type 1 diabetes. Diabetes Care 2003, 26, 837-842.
12. 1c. Diabetes Care 2003, 26, 881-885.
13. Oh, S., M. Lee, K. S. Ko, et al.: GLP-1 gene delivery for the treatment of type 2 diabetes. Mol. Therap. 2003, 7, 478-483.
14. Parsons, G, D. Souza, C. Ford, et al.: Ectopic expression of glucagon-like peptide 1 for gene therapy of type 2 diabetes. Diabetes 2003, 52(suppl 1), A130.
15. Perfetti, R., J. Zhou, M. Doyle, et al.: Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 2000, 141, 4600-4605.
16. Perry, T. A. & N. H. Greig: The glucagon-like peptides: a double-edged therapeutic sword? Trends Pharm. Sd. 2003, 24, 377-383.
17. Prigeon, R. L., S. Quddusi, B. Paty, et al.: Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect. Amer. J. Physiol. Endocrinol. Metab. 2003, 285, E701-E707.
18. Raskin, P. & R. H. Unger: Hyperglucagonemia and its suppression. New Engl. J. Med. 1978, 299, 433-436.
19. Suzuki, A., H. Nakauchi & H. Taniguchi: Glucagon-like peptide 1 (1-37) converts intestinal epithelial cells into insulin-producing cells. Proc. Natl. Acad. Sci. USA 2003, 100, 5034-5039.
20. Tang, S. C. & A. Sambanis: Development of genetically engineered human intestinal cells for regulated insulin secretion using rAAV-mediated gene transfer. Biochem. Biophys. Res. Commun. 2003, 303, 645-652.
21. Wu, L., W. Nicholson, C.Y. Wu, et al.: Engineering physiologically regulated insulin secretion in non-β cells by expressing glucagon-like peptide 1 receptor. Gene Therapy 2003, 10, 1712-1720.
22. Zander, M., S. Madsbad, J. L. Madsen, et al.: Effect of 6-week course of GLP-1 on glycemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002, 359, 824-830.